Diagnosis of brain metastases: An update in 2012;Métastases cérébrales: rôle du pathologiste en 2012

Bulletin du Cancer

Volumn 100, Issue 1, 2013, Pages 29-34

  Lechapt Zalcman, Emmanuèle ^a   Karanian Philippe, Marie ^a   Rousseau, Audrey ^b  

^a CAEN UNIVERSITY HOSPITAL   (France)

^b ANGERS UNIVERSITY HOSPITAL   (France)

Author keywords

Brain metastases; Immunohistochemistry; Pathobiology; Targeted therapy; Unknown primary site

Indexed keywords

BRAIN METASTASIS; CANCER DIAGNOSIS; CANCER THERAPY; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MELANOMA; NEUROPATHOLOGY; REVIEW;

EID: 84875162462     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: 10.1684/bdc.2012.1677     Document Type: Article

References (20)

1. Drlicek M, Bodenteich A, Urbanits S, Grisold W. Immu-nohistochemical panel of antibodies in the diagnosis of brain metastases of the unknown primary. Pathol Res Pract 2004; 200: 727-34.
2. Rochet NM, Kottschade LA, Markovic SN. Vemurafenib for melanoma metastases to the brain. N Engl J Med 2011; 365: 2439-41.
3. Porta R, Sanchez-Torres JM, Paz-Ares L, et al. Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation. Eur Respir J 2011;37: 624-31.
4. Ceresoli GL, Cappuzzo F, Gregorc V, Bartolini S, Crino L, Villa E. Gefitinib in patients with brain metastases from non-small-cell lung cancer: a prospective trial. Ann Oncol 2004; 15: 1042-7.
5. Gow CH, Chien CR, Chang YL, et al. Radiotherapy in lung ade-nocarcinoma with brain metastases: effects of activating epidermal growth factor receptor mutations on clinical response. Clin Cancer Res 2008; 14: 162-8.
6. Conservation et utilisation des échantillons tumoraux en cancérologie-actualisation 2011 des indications et recommanda-tions aux tumorothèques, collection référentielset recommandations, INCa, Boulogne-Billancourt, novembre 2011 (www.ecancer.fr).
7. Lesimple T, Voigt JJ, Bataillard A, et al. Clinical practice guidelines: standards, options and recommendations for the diagnosis of carcinomas of unknown primary site. Bull Cancer 2003;90: 1071-96.
8. Becher MW, Abel TW, Thompson RC, Weaver KD, Davis LE. Immunohistochemical analysis of metastatic neoplasms of the central nervous system. J Neuropathol Exp Neurol 2006;65:935-44.
9. Preusser M, Capper D, Ilhan-Mutlu A, et al. Brain metastases: pathobiology and emerging targeted therapies. Acta Neuropathol 2012;123: 205-22.
10. Dettmer M, Kim TE, Jung CK, Jung ES, Lee KY, Kang CS. Thyroid transcription factor-1 expression in colorectal adenocarcinomas. Pathol Res Pract 2011;207:686-90.
11. Sturm N, Rossi G, Lantuejoul S, et al. Expression of thyroid transcription factor-1 in the spectrum of neuroendocrine cell lung proliferations with special interest in carcinoids. Hum Pathol 2002;33: 175-82.
12. Reis-Filho JS, Tutt AN. Triple negative tumours: a critical review. Histopathology 2008;52:108-18.
13. Wu AH, Drees JC, Wang H, et al. Gene expression profiles help identify the tissue of origin for metastatic brain cancers. Diagn Pathol 2010; 5: 26.
14. Mueller WC, Spector Y, Edmonston TB, et al. Accurate classification of metastatic brain tumors using a novel microRNA-based test. Oncologist 2011; 16: 165-74.
15. Varadhachary GR. Carcinoma ofunknown primary: focused evaluation. J Natl Compr Canc Netw 2011; 9: 1406-12.
16. Flaherty KT, Hodi FS, Fisher DE. From genes to drugs: targeted strategies for melanoma. Nat Rev Cancer 2012;12:349-61.
17. Capper D, Berghoff AS, Magerle M, et al. Immunohistochemical testing of BRAF V600E status in 1, 120 tumor tissue samples of patients with brain metastases. Acta Neuropathol 2012; 123: 223-33.
18. Les tests de génétique moléculaire pour l'accès aux thérapies ciblées. Collection rapports & synthèses, ouvrage collectif édité par l'INCa, Boulogne-Billancourt, décembre 2011. www.ecancer.fr.
19. Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EUR-TAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012;13:239-46.
20. Travis WD, Brambilla E, Noguchi M, et al. International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 2011; 6: 244-85.